Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

October 31, 2014

Conditions
Hypoactive Sexual Desire Disorder
Interventions
DRUG

Placebo

DRUG

0.5 mgTestosterone + 10 mg Buspirone

"A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, on demand) throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days)."

Trial Locations (10)

19224

Philadelphia Clinical Research, LLC, Philadelphia

21093

Maryland Center for Sexual Wellness, Lutherville

21401

Annapolis Sexual Wellness Center, Annapolis

21658

Maryland Primary Care Physicians, Queenstown

32806

Compass Research, Orlando

33409

Comprehensive Clinical Trials LLC, West Palm Beach

33709

Meridien Research, St. Petersburg

34208

Meridien Research, Bradenton

92120

San Diego Sexual Medicine, San Diego

02720

NECCR Fall River LLC, Fall River

Sponsors
All Listed Sponsors
lead

Emotional Brain NY Inc.

INDUSTRY